Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Five volunteers were given Oxford covid-19 vaccine at Pune district Thursday as part of this phase II clinical trial. Three of these volunteers have been administered the Oxford COVID-19 vaccine candidate in Bharti Vidyapeeth’s Medical College and Hospital at Pune town while two more volunteers were inoculated with the Oxford COVID-19 vaccine candidate at the KEM Hospital and Research Centre at Vadu, near Pune, Press Trust of India reported, citing officials.
Here are crucial upgrades of Oxford Covid-19 vaccine trial in India:
The phase II clinical trial of the Oxford covid vaccine in India began on Wednesday in Pune’s Bharti Vidyapeeth’s Medical College and Hospital.
Two volunteers, aged 32 and 48, were provided a shot of the’Covishield’ vaccine on Wednesday.
The 48-year-old volunteer is a Pune-based doctor while the second volunteer is a PhD holder in data and works in a private company.
“Our health care team is in touch with the 2 volunteers and both are fine. They don’t have any pain, fever, injection-side response or systemic illness post-vaccination,” Bharti Vidyapeeth’s Medical College’s deputy director Dr Jitendra Oswal told PTI.
The vaccine dose is going to be replicated on both the volunteers following one month.
The vaccines have been fabricated by the Pune-based Serum Institute of India (SII), the biggest manufacturer of vaccines in the world of vaccines by volume.
Serum Institute has partnered with British-Swedish pharma company AstraZeneca to manufacture covid vaccines manufactured from Oxford University.
The phase-2 trial of Oxford covid vaccine will be run on 100 volunteers in some sites throughout the nation.
Then 1,500 people will be administered that the (possible ) vaccine across the nation in the next stage, based upon the results of the phase II trialperiod.
